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Objectively Measured Secondhand Smoke
Exposure and Risk of Cardiovascular Disease
What Is the Mediating Role of Inflammatory and Hemostatic Factors?
Mark Hamer, PHD,* Emmanuel Stamatakis, PHD,* Mika Kivimaki, PHD,*† Gordon D. Lowe, DSC,‡
G. David Batty, PHD*§
London and Glasgow, United Kingdom; and Helsinki, Finland
Objectives The aim of this study was to examine the association between objectively measured secondhand smoke (SHS)
exposure and incident cardiovascular disease (CVD) death and assess the extent to which this association can
be explained through novel circulating markers of inflammation and hemostasis.
Background Existing evidence suggests there is an association between SHS and CVD risk, although the mechanisms remain
poorly understood.
Methods In a prospective study of 13,443 participants living in England and Scotland (age 53.5  12.6 years, 52.3%
women), we measured salivary cotinine (an objective marker of SHS exposure) and novel CVD biomarkers
(C-reactive protein, fibrinogen) at baseline.
Results Of the sample, 20.8% had high SHS exposure on the basis of elevated levels of salivary cotinine (range 0.71 to
14.99 ng/ml). During a mean follow-up of 8 years, there were 1,221 all-cause deaths and 364 CVD deaths. High
SHS was associated with all-cause (age-adjusted hazard ratio [HR]: 1.25, 95% confidence interval [CI]: 1.02 to
1.53) and CVD death (age-adjusted HR: 1.21, 95% CI: 0.85 to 1.73). High SHS was also associated with elevated
CRP, which explained 48% of the association between SHS and CVD death. The excess risk of CVD associated
with active smoking was exaggerated in relation to self report (age-adjusted HR: 3.27, 95% CI: 2.48 to 4.31)
compared with objective assessment (age-adjusted HR: 2.44, 95% CI: 1.75 to 3.40).
Conclusions Among a large representative sample of British adults we observed elevated levels of low-grade inflammation in
otherwise healthy participants exposed to high SHS, and this partly explained their elevated risk of CVD
death. (J Am Coll Cardiol 2010;56:18–23) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.032f
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decent studies that have used valid objective biochemical
arkers of secondhand smoke (SHS) exposure have found
ssociations with various cardiovascular disease (CVD) risk
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010, accepted March 18, 2010.actors, including socioeconomic deprivation, markers of
nflammation, endothelial dysfunction, lipids, and glucose
ontrol (1–4). To our knowledge, there are only 2 studies to
ate that have examined CVD mortality risk with objec-
ively measured biomarkers of SHS exposure (4,5), although
of these studies (5) used carboxyhemoglobin concentra-
ion that is not a useful indicator of SHS.
Mechanisms explaining the association between SHS expo-
ure and coronary heart disease risk have not been well-
xamined. The suggestion that the association between SHS
nd CHD is not markedly attenuated by adjustment for
onventional CVD risk factors, such as blood pressure, blood
ipids, body mass index, and fasting glucose, raises the possi-
ility that other, novel explanatory factors might be involved.
he importance of low-grade inflammation in the link be-
ween active smoking and CVD risk is increasingly recognized
6,7), but we are not aware of any existing study that has
irectly assessed the role of inflammatory and hemostatic
arkers in relation to SHS exposure.
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June 29, 2010:18–23 Cotinine Level, Inflammation, and Cardiovascular DiseaseIn the present study, we examined the association be-
ween objectively measured SHS and incident CVD death
nd assessed the extent to which this association could be
xplained through 2 circulating markers of inflammation
nd hemostasis: C-reactive protein (CRP) (8) and fibrino-
en (9). We employed salivary cotinine as an objective
ndicator of nicotine exposure that is considered to be the
old standard measure (10).
ethods
tudy design and participants. The Health Survey for
ngland and Scottish Health Survey are annual, ongoing,
epeated, cross-sectional, general population-based studies
xamining individuals living in households in each country
11,12). In the present sample we amalgamated data from
oth the Scottish Health Survey (1998, 2003) and Health
urvey for England (1998, 1999, 2003, 2004). Consenting
tudy members (94% in Health Surveys for England, 82.5%
n Scottish Health Surveys) were linked to National Health
ervice mortality data. The final analytic sample consisted
f 13,443 men and women over 35 years of age and free of
VD or cancer (for sample selection, see the Online
ppendix). Study participants gave full informed consent
nd ethical approval was obtained from the London Re-
earch Ethics Council.
ssessment of direct and SHS exposure. Data on self-
eported smoking were collected with standard methods
11,12) and classified into 3 groups (current/ex-smoker/
ever). Exposure to SHS was assessed with salivary cotinine,
hich is a reliable and valid circulating biochemical marker
f nicotine exposure (10). A dental roll saturated with
articipants’ saliva was placed in a tube and later analyzed
ith a Hewlett Packard hp5890 gas chromatograph (Palo
lto, California), with a rapid-liquid chromatography tech-
ique (coefficient of variation [CV] 7%). Participants
eporting nonsmoking status but with salivary cotinine 15
g/ml were re-categorized as smokers, in keeping with other
nalyses (1,4).
emographic and clinical variables. Computer-assisted
ersonal interviewing modules assessed respondents’ demo-
raphic data, mental health status, history of disease, and
ealth behaviors. In a separate visit, qualified nurses col-
ected blood samples and measured seated blood pressure.
lood samples were analyzed for CRP, fibrinogen, and total
nd high-density lipoprotein (HDL) cholesterol. The anal-
sis of CRP levels from serum was performed with the N
atex high-sensitivity CRP mono immunoassay on the
ehring Nephelometer II analyzer (Dade Behring, Mar-
urg, Germany) (CV 6%). Fibrinogen levels were deter-
ined with the Organon Teknika MDA 180 analyzer
Organon, Teknika, Durham, North Carolina), with a
odification of the Clauss thrombin clotting method (CV
10%). Cholesterol and HDL cholesterol was measured
ith cholesterol oxidase assays on an Olympus 640 analyzer
Olympus, Center Valley, Pennsylvania). sortality follow-up. Diagnoses
or primary cause of death was
ecorded with the International
lassification of Diseases-9th
ICD-9) and -10th Revisions
ICD-10) Revisions. Cardiovas-
ular disease codes were 390-459
or ICD-9 and I01-I99 for
CD-10.
tatistical analysis. Exposure to
icotine was categorized into 4
roups, representing “low” SHS
salivary cotinine 0.05 ng/ml),
moderate” SHS (0.06 to 0.70 ng/ml), “high” SHS (0.71 to
4.99 ng/ml), and “current smoker” (on the basis of self
eport or cotinine 15 ng/ml). This categorization of SHS
as based on previous evidence for health effects at this level
f exposure (1,4). We used general linear models to examine
he association between SHS and biological risk factors.
he CRP data were log transformed to normalize the
istribution. We used Cox proportional hazards models to
ompute hazard ratios (HRs) with accompanying 95%
onfidence intervals (CIs) for the association between coti-
ine levels and CVD death/all-cause death. The propor-
ional hazards assumption was examined by comparing the
umulative hazard plots grouped on exposure, although no
ppreciable violations were noted. In these analyses, calen-
ar time (months) was the time scale. For participants that
emained alive, the data were censored on February 28,
008, in the Health Survey for England and December 30,
008, in the Scottish Health Survey. There were no clear
ifferences in our results between men and women, so the
ata were pooled and sex-adjusted. We fitted several mu-
ually exclusive models, and the percentage change in HR
fter multiple adjustments in comparison with the basic
age-adjusted) model was quantified as follows: (HRbasic model
HRadjusted)/(HRbasic model  1)  100 (13). The “non-
moking” group consisted of both never and ex-smokers,
lthough we conducted sensitivity analyses to examine
ssociations among both groups separately. Statistical sig-
ificance of p  0.05 was employed throughout. All
nalyses were conducted with SPSS version 14 (SPSS Inc.,
hicago, Illinois).
esults
haracteristics. In the present sample, 28.7% of partici-
ants were classified as smokers and 20.8% had high SHS
xposure on the basis of levels of salivary cotinine. There
as a dose-response relationship between self-reported
moking and cotinine values (Fig. 1). Never smokers and
x-smokers did not differ significantly in levels of salivary
otinine. In comparison with those with lower SHS expo-
ure, both smokers and participants with high SHS were
ounger, more likely to be male, come from lower social-
Abbreviations
and Acronyms
CI  confidence interval
CRP  C-reactive protein
CV  coefficient of
variation
CVD  cardiovascular
disease
HDL  high-density
lipoprotein
SHS  secondhand smoketatus groups, live in Scotland, and be less physically active
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Cotinine Level, Inflammation, and Cardiovascular Disease June 29, 2010:18–23Table 1). Levels of psychological distress were significantly
levated in smokers. Self-reported diabetes was not associ-
ted with smoking and only marginally associated with SHS
xposure.
orrelations with inflammatory markers. Cigarette smok-
ng was related to increased levels of fibrinogen, CRP, and
ower HDL cholesterol (Table 2). High SHS was associated
ith elevated CRP and blood pressure compared with low
HS. There were also significant associations of CRP and
brinogen with age, female sex (for fibrinogen), lower
hysical activity, and low social status/survey location (On-
ine Table A1).
otinine and risk of CVD and all-cause death. Over an
verage follow-up period of 8.0 years (range 1 to 128
onths) there were 1,221 all-cause deaths and 364 CVD
eaths. As anticipated, conventional risk factors were asso-
iated with CVD death (Online Table B1). In the total
ohort, the association between SHS category and CVD did
ot reach conventional levels of statistical significance,
lthough log cotinine as a continuous variable was associ-
ted with CVD (per-unit increase; HR: 1.21, 95% CI: 1.15
o 1.25) (Table 3). When we restricted analyses to never-
mokers, high SHS exposure was associated with over a
Figure 1 Median Salivary Cotinine Levels in Relation to Self-Re
There was a dose-response relationship between self-reported smoking (cigarettes
Never smokers and ex-smokers did not differ significantly in levels of salivary cotin
aseline Characteristics of the Study Participants According to NicTable 1 Baseline Characteristics of the Study Participants Acc
Nonsmoker (Cotinine Level, n
<0.06
(n  1,703)
0.06–0.70
(n  5,089)
Age (yrs) 55.6 13.5 54.2 12.9
Sex (men) 41.0 44.0
Lower social status (IV/V) 12.4 14.1
Nationality (Scottish) 49.3 55.0
Psychological distress 11.5 12.1
Weekly MVPA (none) 50.6 48.5
Doctor-diagnosed diabetes 2.9 2.4 13,443. Data given as mean  SD or percentages. *Trend across nonsmokers; †trend across whole
IV/V  part skilled/unskilled; MVPA  moderate–vigorous physical activity.-fold increased risk of CVD death (Table 3), although
here was no association in ex-smokers (HR: 0.87, 95% CI:
.55 to 1.36). On the basis of self-report, ex-smokers were
t elevated risk of CVD compared with never smokers (HR:
.38, 95% CI: 1.07 to 1.78).
In the total cohort there was a significant association
etween SHS exposure and all-cause mortality (Table 4).
e observed stronger associations in never-smokers (HR:
.33, 95% CI: 0.94 to 1.88) than in ex-smokers (HR: 1.14,
5% CI: 0.89 to 1.48) although not reaching conventional
evels of statistical significance. The removal of 56 deaths
ithin the first 2 years of follow-up did not substantially
lter these results.
roportion of cotinine–CVD association explained by
nflammatory markers. When we included all biological
isk factors in the models for the total sample, the HR for
igh SHS and CVD death was attenuated by 48% (Table 3)
nd by 40% in the case of all-cause mortality (Table 4). This
ffect was almost entirely explained by CRP, because re-
oval of other risk factors did not impact the result. When
ehavioral and psychosocial covariates (in addition to bio-
ogical variables) were included in a fully adjusted model,
he point estimate was attenuated to the null. In the case of
d Smoking Status
and cotinine values.
Exposureg to Nicotine Exposure
Smoker
(n  3,859)
p Value for
Trend*
p Value for
Trend†
.71–14.99
 2,793)
3.7 12.5 50.8 11.4 0.001 0.001
52.7 51.7 0.001 0.001
20.3 27.8 0.001 0.001
57.6 61.0 0.001 0.001
13.4 18.6 0.125 0.001
55.1 63.3 0.001 0.001
3.3 2.3 0.06 0.52porte
/day)
ine.otineordin
g/ml)
0
(n
5sample.
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June 29, 2010:18–23 Cotinine Level, Inflammation, and Cardiovascular Diseasemoking, however, there remained an elevated risk despite
ull adjustments. When we focused on men and women who
eported never smoking, there remained over a 2-fold
ncreased risk of CVD death for high SHS that was
inimally affected by adjustment for biological covariates.
he excess risk was exactly 2-fold after full adjustment for
ll risk factors.
iscussion
he aim of the present study was to examine the association
etween objectively measured SHS and incident CVD
eath and the extent to which this association could be
xplained through novel (nonconventional) mechanisms.
irst, there was an association of SHS exposure with
ll-cause mortality and CVD death, which confirms results
rom 2 previous studies (4,5). We observed elevated levels of
ow-grade inflammation, indexed by CRP, in participants
xposed to high SHS, and this partly explained the elevated
isk of CVD and all-cause death associated with high SHS
n the total cohort but not in the sub-group of never
mokers.
Previous studies on the association between SHS expo-
ure and markers of inflammation and hemostasis have
roduced inconsistent findings. In a Greek population
tudy, participants with a self-reported exposure to SHS on
ore than 3 days/week demonstrated elevated levels of
RP, fibrinogen, and white blood cell counts (14), and
ssociation Among SHS Exposure, Smoking, and CVD Risk MarkerTable 2 Association Among SHS Exposure, Smoking, and CVD
Exposure (Cotinine Level)
Fibrinogen
 (95% CI)
Low SHS (0.06 ng/ml) 0 (Reference)
Medium SHS (0.06–0.70 ng/ml) 0.01 (0.04 to 0.03) 0.00
High SHS (0.71–14.99 ng/ml) 0.01 (0.03 to 0.04) 0.0
Smokers (15.00 ng/ml) 0.30 (0.26 to 0.34) 0.2
p value for trend 0.001
 13,443. Models adjusted for age and sex. -coefficients represent mean differences compar
BP  blood pressure; CI  confidence interval; CRP  C-reactive protein; CVD  cardiovascula
ox Proportional Hazards Models of SHS Exposure, Smoking, and CTable 3 Cox Proportional Hazards Models of SHS Exposure, Sm
Exposure Event/N Age-Adjusted Mo
All 364/13,443
Low SHS 52/1,703 1.00 (Reference) 1
Medium SHS 114/5,088 0.89 (0.64–1.23) 0.88 (0
High SHS 73/2,793 1.21 (0.85–1.73) 1.08 (0
Smokers 125/3,859 2.44 (1.75–3.40) 2.12 (1
Log cotinine (/U) 1.21 (1.15–1.25) 1.18 (1
Never-smokers 96/5,500
Low SHS 15/1,025 1.00 1
Medium SHS 49/3,024 1.28 (0.72–2.28) 1.28 (0
High SHS 32/1,455 2.22 (1.20–4.12) 2.02 (1
Log cotinine (/U) 1.72 (1.21–2.44) 1.62 (1
alues are hazard ratio (95% CI) unless otherwise indicated. All models are mutually exclusive of o
/week, 3/week). Model 2 (psychosocial), adjusted for age, sex, social status (I/II profession
cotland), psychological distress (General Health Questionnaire -12 4 or 4). Model 3 (biological), adju
Abbreviations as in Table 2.mong Japanese women, exposure to SHS outside the home
as related to elevated fibrinogen (15). In studies that have
mployed objective measures of SHS, data from the Third
ational Health and Nutrition Examination Survey found
ssociations of high SHS with fibrinogen but not CRP and
hite cell count (3), although the British Regional Heart
tudy demonstrated positive associations with all of these
iomarkers, plus interleukin-6 and von Willebrand factor
1). Previous studies have reported, on the basis of self-
eported SHS exposure, modest—typically 1.2- to 1.3-
old—increase in risk of CVD (16). A 1.4-fold increased
isk was reported in a study using objective measures (4).
ur data with a 1.2-fold excess risk for high SHS and CVD
eath in the total cohort is largely comparable with these
gures, except for the associations in “never-smokers” that is
ar larger than previous reports. In the case of “never-
mokers” there remained a 2-fold increased risk of CVD
eath for high SHS exposure after full adjustment for
sychosocial, behavioral, and biological risk factors. In never
mokers the associations of SHS with inflammatory and
emostatic risk factors were nonsignificant (data not
hown), which is consistent with previous findings (1).
hus, other mechanisms might be responsible for the excess
isk of CVD. For example, experimental data suggests that
HS exposure can elicit acute endothelial dysfunction,
lthough precise mechanisms remain unclear because the
ffects of SHS on the number and functional activity of
aselineMarkers at Baseline
CRP
% CI)
Systolic BP
 (95% CI)
HDL-C
 (95% CI)
ence Reference Reference
04 to 0.04) 0.20 (1.14 to 0.73) 0.002 (0.03 to 0.03)
to 0.13) 1.30 (0.26 to 2.33) 0.006 (0.02 to 0.03)
to 0.32) 0.22 (1.20 to 0.76) 0.08 (0.10 to 0.05)
001 0.001 0.001
reference group.
e; HDL-C  high-density lipoprotein cholesterol; SHS  secondhand smoke.
ortalityg, and CVD Mortality
Model 2 Model 3 Fully Adjusted
1.00 1.00 1.00
22) 0.85 (0.61–1.18) 0.88 (0.64–1.23) 0.86 (0.62–1.19)
54) 1.00 (0.69–1.43) 1.11 (0.77–1.58) 0.97 (0.68–1.40)
97) 2.03 (1.45–2.85) 2.04 (1.46–2.86) 1.74 (1.24–2.46)
23) 1.17 (1.12–1.23) 1.16 (1.12–1.22) 1.14 (1.09–1.19)
1.00 1.00 1.00
28) 1.28 (0.71–2.29) 1.35 (0.75–2.42) 1.33 (0.74–2.39)
75) 1.98 (1.05–3.72) 2.22 (1.19–4.15) 2.00 (1.06–3.78)
32) 1.60 (1.11–2.30) 1.69 (1.18–2.42) 1.60 (1.11–2.31)
ther. Model 1 (behavioral), adjusted for age, sex, moderate–vigorous physical activity (none, up to
rmediate, III skilled nonmanual/manual, IV/V part skilled/unskilled), survey location (England,s at BRisk
Log
 (95
Refer
2 (0.
8 (0.04
8 (0.24
0.VD Mokin
del 1
.00
.63–1.
.75–1.
.52–2.
.13–1.
.00
.71–2.
.09–3.
.13–2.
ne ano
al/intested for age, sex, log C-reactive protein, fibrinogen, HDL-C, systolic blood pressure.
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Cotinine Level, Inflammation, and Cardiovascular Disease June 29, 2010:18–23irculating endothelial progenitor cells is inconsistent
17,18). This mechanism might account for the association
f SHS with circulating markers of endothelial cell activa-
ion, such as von Willebrand factor (1). Interestingly, there
as no association between SHS exposure and CVD in
x-smokers. This might be partly because ex-smokers al-
eady have heightened risk of CVD in comparison with
ever-smokers, thus SHS exposure might not add to exist-
ng risk. Indeed, inflammatory mediators like CRP are still
ignificantly raised in ex-smokers up to 10 to 20 years after
uitting (7), suggesting a persistent low-grade inflammatory
esponse in former smokers. Former smokers might also be
dvised to quit because of existing health problems; thus,
he associations might in part also be explained by reverse
ausation. Our data confirm the strong association between
ctive smoking and CVD/all-cause mortality (19), although
he estimated effects were lower when using the objective
ndicator.
The present data were collected before the introduction
f smoke-free legislation in England and Scotland. The
moking ban seems to have already had a considerable
mpact on the health of the British population (20), al-
hough we were unable to estimate the effects of this
ntervention in these analyses, because follow-up data on
otinine were not available. However, we would not expect
hat our results have been confounded by the smoking ban,
ecause our study includes only 7 months of CVD deaths
fter the introduction of the ban (July 2007). We were also
nable, due to the lack of follow-up data on cotinine, to
ccount for the effects of changes in smoking behavior that
re known to fluctuate over time. There was a large amount
f missing data on alcohol intake and body mass index; thus,
e were unable to account for these factors in our analyses.
owever, analyses in a smaller sub-sample of participants
ith available data on alcohol and body mass index sug-
ested that the association between SHS exposure and
ox Proportional Hazards Models of SHS Exposure, Smoking, and ATable 4 Cox Proportional Hazards Models of SHS Exposure, Sm
Exposure Event/N Age-Adjusted M
All 1,221/13,443
Low SHS 153/1,703 1.00
Medium SHS 349/5,088 0.89 (0.74–1.08) 0.88 (
High SHS 233/2,793 1.25 (1.02–1.53) 1.15 (
Smokers 487/3,859 2.89 (2.40–3.48) 2.60 (
Log cotinine (/U) 1.23 (1.21–1.26) 1.21 (
Never-smokers 273/5,500
Low SHS 56/1,025 1.00
Medium SHS 142/3,024 0.97 (0.71–1.32) 0.96 (
High SHS 75/1,455 1.33 (0.94–1.88) 1.26 (
Log cotinine (/U) 1.26 (0.99–1.60) 1.21 (
alues are hazard ratio (95% CI) unless otherwise indicated. All models are mutually exclusive of o
/week,3 /week). Model 2 (psychosocial), adjusted for age, sex, social status (I/II, III, IV/V), surve
(biological), adjusted for age, sex, log C-reactive protein, fibrinogen, HDL-C, systolic blood pressu
Abbreviations as in Tables 2 and 3.VD was not explained by these variables.In summary, very few large-scale population-based stud-
es have collected objective biochemical markers of SHS
xposure with follow-up data on mortality. Thus, we have
resented novel data on the association between objectively
easured SHS and incident CVD death in a nationally
epresentative sample of British adults. We observed ele-
ated levels of low-grade inflammation in otherwise healthy
articipants exposed to high SHS, and this partly explained
heir elevated risk of CVD death.
eprint requests and correspondence: Dr. Mark Hamer, De-
artment of Epidemiology and Public Health, University College
ondon, 1-19 Torrington Place, London WC1E 6BT, United
ingdom. E-mail: m.hamer@ucl.ac.uk.
EFERENCES
1. Jefferis BJ, Lowe GD, Welsh P, et al. Secondhand smoke (SHS)
exposure is associated with circulating markers of inflammation and
endothelial function in adult men and women. Atherosclerosis 2010;
208:550–6.
2. Houston TK, Person SD, Pletcher MJ, Liu K, Iribarren C, Kiefe CI.
Active and passive smoking and development of glucose intolerance
among young adults in a prospective cohort: CARDIA study. BMJ
2006;332:1064–9.
3. Venn A, Britton J. Exposure to secondhand smoke and biomarkers of
cardiovascular disease risk in never-smoking adults. Circulation 2007;
115:990–5.
4. Whincup PH, Gilg JA, Emberson JR, et al. Passive smoking and risk
of coronary heart disease and stroke: prospective study with cotinine
measurement. BMJ 2004;329:200–5.
5. Hart CL, Smith GD, Hole DJ, Hawthorne VM. Carboxyhaemo-
globin concentration, smoking habit, and mortality in 25 years in
the Renfrew/Paisley prospective cohort study. Heart 2006;92:
321–4.
6. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK.
Relationship between cigarette smoking and novel risk factors for
cardiovascular disease in the United States. Ann Intern Med
2003;138:891–7.
7. Wannamethee SG, Lowe GD, Shaper AG. Associations between
cigarette smoking, pipe/cigar smoking, and smoking cessation, and
haemostatic and inflammatory markers for cardiovascular disease. Eur
use Mortalityg, and All-Cause Mortality
Model 2 Model 3 Fully Adjusted
1.00 1.00 1.00
.07) 0.85 (0.70–1.03) 0.89 (0.74–1.08) 0.86 (0.71–1.05)
.42) 1.07 (0.87–1.31) 1.15 (0.93–1.41) 1.03 (0.83–1.27)
.14) 2.44 (2.02–2.95) 2.52 (2.09–3.04) 2.19 (1.81–2.65)
.24) 1.21 (1.18–1.24) 1.21 (1.18–1.21) 1.18 (1.16–1.21)
1.00 1.00 1.00
.31) 0.94 (0.69–1.28) 1.00 (0.73–1.36) 0.98 (0.71–1.33)
.79) 1.24 (0.87–1.77) 1.31 (0.92–1.86) 1.27 (0.89–1.81)
.55) 1.21 (0.95–1.55) 1.24 (0.97–1.58) 1.21 (0.95–1.55)
ther. Model 1 (behavioral), adjusted for age, sex, moderate-vigorous physical activity (none, up to
on (England, Scotland), psychological distress (General Health Questionnaire-124 or4). Modelll-Caokin
odel 1
1.00
0.73–1
0.94–1
2.16–3
1.19–1
1.00
0.70–1
0.89–1
0.95–1
ne ano
y locatiHeart J 2005;26:1765–73.
11
1
1
1
1
1
1
1
1
2
K
n
F
23JACC Vol. 56, No. 1, 2010 Hamer et al.
June 29, 2010:18–23 Cotinine Level, Inflammation, and Cardiovascular Disease8. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and
other circulating markers of inflammation in the prediction of coronary
heart disease. N Engl J Med 2004;350:1387–97.
9. Danesh J, Lewington S, Thompson SG, et al., Fibrinogen Studies
Collaboration. Plasma fibrinogen level and the risk of major cardio-
vascular diseases and nonvascular mortality: an individual participant
meta-analysis. JAMA 2005;294:1799–809.
0. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y.
Comparison of tests used to distinguish smokers from nonsmokers.
Am J Public Health 1987;77:1435–8.
1. The Scottish Government Statistics. Scottish Health Survey Publications.
Available at: http://www.scotland.gov.uk/Topics/Statistics/Browse/
Health/scottish-health survey/Publications. Accessed November 2007.
2. Joint Health Surveys Unit. Health Survey for England 1998. Cardio-
vascular Disease. Volume 2: Methodology and Documentation. Lon-
don: The Stationery Office, 1999.
3. Hamer M, Molloy GJ, Stamatakis E. Psychological distress as a risk
factor for cardiovascular events: pathophysiological and behavioral
mechanisms. J Am Coll Cardiol 2008;52:2156–62.
4. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Effect of exposure
to secondhand smoke on markers of inflammation: the ATTICA
study. Am J Med 2004;116:145–50.
5. Iso H, Shimamoto T, Sato S, Koike K, Iida M, Komachi Y. Passive
smoking and plasma fibrinogen concentrations. Am J Epidemiol
1996;144:1151–4. p6. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke:
nearly as large as smoking. Circulation 2005;111:2684–98.
7. Raupach T, Schäfer K, Konstantinides S, Andreas S. Secondhand
smoke as an acute threat for the cardiovascular system: a change in
paradigm. Eur Heart J 2006;27:386–92.
8. Heiss C, Amabile N, Lee AC, et al. Brief secondhand smoke
exposure depresses endothelial progenitor cells activity and endo-
thelial function: sustained vascular injury and blunted nitric oxide
production. J Am Coll Cardiol 2008;51:1760–71.
9. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to
smoking: 50 years’ observations on male British doctors. BMJ 2004;
328:1519.
0. Pell JP, Haw S, Cobbe S, et al. Smoke-free legislation and
hospitalizations for acute coronary syndrome. N Engl J Med
2008;359:482–91.
ey Words: cotinine y epidemiology y inflammation y mortality y
icotine y passive smoke.
APPENDIX
or supplementary tables and Methods,
lease see the online version of this article.
